This is a Validated Antibody Database (VAD) review about human MGMT, based on 24 published articles (read how Labome selects the articles), using MGMT antibody in all methods. It is aimed to help Labome visitors find the most suited MGMT antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MGMT synonym: methylated-DNA--protein-cysteine methyltransferase; 6-O-methylguanine-DNA methyltransferase; O-6-methylguanine-DNA-alkyltransferase; O6-methylguanine-DNA methyltransferase; methylguanine-DNA methyltransferase

Invitrogen
mouse monoclonal (MT 3.1)
  • immunohistochemistry - paraffin section; human; 1:20; loading ...; fig 5e
In order to discuss therapeutic options available for patients with adrenocortical carcinomas, Invitrogen MGMT antibody (Thermo Fisher, MT 3.1) was used in immunohistochemistry - paraffin section on human samples at 1:20 (fig 5e). J Clin Endocrinol Metab (2016) ncbi
mouse monoclonal (MT 3.1)
  • immunohistochemistry; human; 1:20; tbl 2
In order to identify immunohistological features that distinguish hereditary colorectal cancer from spontaneous cases, Invitrogen MGMT antibody (Thermo Scientific, MT 3.1) was used in immunohistochemistry on human samples at 1:20 (tbl 2). Virchows Arch (2016) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; fig 3
In order to study tumor periphery glioma cells and their stem cell phenotype, Invitrogen MGMT antibody (Invitrogen, MT23.2) was used in immunohistochemistry - paraffin section on human samples (fig 3). PLoS ONE (2016) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; fig 3
In order to study tumor periphery glioma cells and their stem cell phenotype, Invitrogen MGMT antibody (Invitrogen, MT23.2) was used in immunohistochemistry - paraffin section on human samples (fig 3). PLoS ONE (2016) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
In order to analyze the Children's Oncology Group ACNS0423 phase 2 study of concurrent temozolomide and radiotherapy followed by lomustine and temozolomide in treatment of children with high-grade glioma, Invitrogen MGMT antibody (Zymed, mT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4). Neuro Oncol (2016) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
In order to analyze the Children's Oncology Group ACNS0423 phase 2 study of concurrent temozolomide and radiotherapy followed by lomustine and temozolomide in treatment of children with high-grade glioma, Invitrogen MGMT antibody (Zymed, mT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4). Neuro Oncol (2016) ncbi
mouse monoclonal (MT 3.1)
  • western blot; human; fig 6
In order to discover enhancment of temozolomide-induced growth suppression of mutant EFGR in glioma cells in vivo by nimotuzumab, Invitrogen MGMT antibody (Neo Markers, MT3.1) was used in western blot on human samples (fig 6). Cancer Med (2016) ncbi
mouse monoclonal (MT23.2)
  • western blot; human
In order to show that UBR1 regulates MGMT homeostasis and DNA repair of alkylated DNA adducts in cells, Invitrogen MGMT antibody (Invitrogen, 35-7000) was used in western blot on human samples . Cancer Res (2015) ncbi
mouse monoclonal (MT 3.1)
  • immunohistochemistry; human; 1:200
Invitrogen MGMT antibody (LabVision, MT3.1) was used in immunohistochemistry on human samples at 1:200. Int Urol Nephrol (2015) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to discuss the use of temozolomide to treat pituitary tumors, Invitrogen MGMT antibody (Invitrogen, clone MT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). J Clin Endocrinol Metab (2015) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to discuss the use of temozolomide to treat pituitary tumors, Invitrogen MGMT antibody (Invitrogen, clone MT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). J Clin Endocrinol Metab (2015) ncbi
mouse monoclonal (MT 3.1)
  • western blot; human; fig 1
In order to report the effects of new temozolomide analogues on glioblastoma multiforme, Invitrogen MGMT antibody (Thermo Scientific, MS-470-P) was used in western blot on human samples (fig 1). Mol Cancer Ther (2015) ncbi
mouse monoclonal (MT 23.2)
  • immunocytochemistry; human; 1:50
  • western blot; human; 1:50
Invitrogen MGMT antibody (Zymed, MT23.2) was used in immunocytochemistry on human samples at 1:50 and in western blot on human samples at 1:50. Cell Stress Chaperones (2015) ncbi
mouse monoclonal (MT23.2)
  • immunocytochemistry; human; 1:50
  • western blot; human; 1:50
Invitrogen MGMT antibody (Zymed, MT23.2) was used in immunocytochemistry on human samples at 1:50 and in western blot on human samples at 1:50. Cell Stress Chaperones (2015) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; 1:50; fig 4
In order to examine heat shock proteins in different subtypes of gliomas, Invitrogen MGMT antibody (Zymed, clone MT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 4). Cell Stress Chaperones (2012) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; 1:50; fig 4
In order to examine heat shock proteins in different subtypes of gliomas, Invitrogen MGMT antibody (Zymed, clone MT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 4). Cell Stress Chaperones (2012) ncbi
mouse monoclonal (MT 3.1)
  • immunohistochemistry - paraffin section; human; 1:500
In order to study methylation of the O6-methylguanine-DNA-methyltransferase promoter in patients with glioblastoma, Invitrogen MGMT antibody (Neomarkers, MT 3.1) was used in immunohistochemistry - paraffin section on human samples at 1:500. Clinics (Sao Paulo) (2011) ncbi
mouse monoclonal (MT 3.1)
  • immunohistochemistry - paraffin section; human; 1:400
In order to investigate the existence of brain tumor stem cells, Invitrogen MGMT antibody (Lab Vision, MS-470-P0) was used in immunohistochemistry - paraffin section on human samples at 1:400. J Oncol (2011) ncbi
mouse monoclonal (MT23.2)
  • flow cytometry; human; tbl 1
  • immunohistochemistry; human
In order to review methods to analyze O6-Methylguanine-DNA methyltransferase, Invitrogen MGMT antibody (Zymed, MT23.2) was used in flow cytometry on human samples (tbl 1) and in immunohistochemistry on human samples . BMC Cancer (2011) ncbi
mouse monoclonal (MT 3.1)
  • immunohistochemistry; human
In order to review methods to analyze O6-Methylguanine-DNA methyltransferase, Invitrogen MGMT antibody (Neomarkers, MT3.1) was used in immunohistochemistry on human samples . BMC Cancer (2011) ncbi
mouse monoclonal (MT 23.2)
  • flow cytometry; human; tbl 1
  • immunohistochemistry; human
In order to review methods to analyze O6-Methylguanine-DNA methyltransferase, Invitrogen MGMT antibody (Zymed, MT23.2) was used in flow cytometry on human samples (tbl 1) and in immunohistochemistry on human samples . BMC Cancer (2011) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 6
In order to discuss indicators of tumor aggressiveness for pilocytic astrocytoma, Invitrogen MGMT antibody (Zymed, mT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6). Brain Pathol (2010) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 6
In order to discuss indicators of tumor aggressiveness for pilocytic astrocytoma, Invitrogen MGMT antibody (Zymed, mT23.2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6). Brain Pathol (2010) ncbi
mouse monoclonal (MT 23.2)
  • immunohistochemistry - paraffin section; human; fig 3
In order to investigate the role of DNA repair proteins and their prognostic significance in non-small-cell lung cancer, Invitrogen MGMT antibody (Zymed, MT23.2) was used in immunohistochemistry - paraffin section on human samples (fig 3). Histopathology (2008) ncbi
mouse monoclonal (MT23.2)
  • immunohistochemistry - paraffin section; human; fig 3
In order to investigate the role of DNA repair proteins and their prognostic significance in non-small-cell lung cancer, Invitrogen MGMT antibody (Zymed, MT23.2) was used in immunohistochemistry - paraffin section on human samples (fig 3). Histopathology (2008) ncbi
Novus Biologicals
mouse monoclonal (MT 23.2)
  • immunohistochemistry; human; loading ...; fig s1b
In order to describe the mechanism behind the association between single nucleotide polymorphism rs55705857 and glioma development., Novus Biologicals MGMT antibody (Novus Biologicals, NB100-168) was used in immunohistochemistry on human samples (fig s1b). Sci Rep (2016) ncbi
mouse monoclonal (MT 23.2)
  • western blot; human; fig 6
In order to determine the promotion of genomic and phenotypic changes in glioblastoma cells by temozolomide, Novus Biologicals MGMT antibody (Novus Biologicals, NB100-168) was used in western blot on human samples (fig 6). Cancer Cell Int (2016) ncbi
mouse monoclonal (MT 23.2)
  • western blot; human; 1:1000; fig s1d
In order to investigate the role of protein stability in the choice of DNA repair mechanism, Novus Biologicals MGMT antibody (Novus, NB100-168) was used in western blot on human samples at 1:1000 (fig s1d). Nat Commun (2014) ncbi
Abcam
mouse monoclonal (MT3.1)
  • immunohistochemistry; human; loading ...; fig s2
Abcam MGMT antibody (Abcam, ab39253) was used in immunohistochemistry on human samples (fig s2). Cancer Lett (2015) ncbi
mouse monoclonal (MT3.1)
  • western blot; human; fig 3d, 3e, 3f
Abcam MGMT antibody (Abcam, ab39253) was used in western blot on human samples (fig 3d, 3e, 3f). Int J Oncol (2014) ncbi
Cell Signaling Technology
rabbit polyclonal
  • western blot; human; loading ...; fig 1
In order to report the effects of NVP-CGM097 on the p53wildtype GOT1 cells, Cell Signaling Technology MGMT antibody (Cell Signaling, 2739) was used in western blot on human samples (fig 1). Neuroendocrinology (2018) ncbi
rabbit polyclonal
  • western blot; human; loading ...; fig 4
In order to propose using three-dimensional collagen scaffolds to study anti-glioma therapeutics, Cell Signaling Technology MGMT antibody (Cell Signaling, 2739S) was used in western blot on human samples (fig 4). Oncotarget (2016) ncbi
BD Biosciences
mouse monoclonal (MT5.1)
  • western blot; human; loading ...; fig 1a
BD Biosciences MGMT antibody (BD Pharmingen, 557045) was used in western blot on human samples (fig 1a). Oncotarget (2015) ncbi
Articles Reviewed
  1. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106:1-19 pubmed publisher
  2. Creemers S, van Koetsveld P, van den Dungen E, Korpershoek E, van Kemenade F, Franssen G, et al. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. J Clin Endocrinol Metab. 2016;101:4574-4584 pubmed
  3. Lv D, Yu S, Ping Y, Wu H, Zhao X, Zhang H, et al. A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics. Oncotarget. 2016;7:56904-56914 pubmed publisher
  4. Oktay Y, Ãœlgen E, Can Ã, Akyerli C, Yüksel Å, Erdemgil Y, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Sci Rep. 2016;6:27569 pubmed publisher
  5. Boissière Michot F, Frugier H, Ho Pun Cheung A, Lopez Crapez E, Duffour J, Bibeau F. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. Virchows Arch. 2016;469:135-44 pubmed publisher
  6. Munthe S, Petterson S, Dahlrot R, Poulsen F, Hansen S, Kristensen B. Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype. PLoS ONE. 2016;11:e0155106 pubmed publisher
  7. Stepanenko A, Andreieva S, Korets K, Mykytenko D, Baklaushev V, Huleyuk N, et al. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. Cancer Cell Int. 2016;16:36 pubmed publisher
  8. Jakacki R, Cohen K, Buxton A, Krailo M, Burger P, Rosenblum M, et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol. 2016;18:1442-50 pubmed publisher
  9. Nitta Y, Shimizu S, Shishido Hara Y, Suzuki K, Shiokawa Y, Nagane M. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med. 2016;5:486-99 pubmed publisher
  10. Ramcharan R, Aleksic T, Kamdoum W, Gao S, Pfister S, Tanner J, et al. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. Oncotarget. 2015;6:39877-90 pubmed publisher
  11. Leng S, Wu G, Collins L, Thomas C, Tellez C, Jauregui A, et al. Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung. Cancer Res. 2015;75:3108-17 pubmed publisher
  12. Bánfi G, Teleki I, Nyirády P, Keszthelyi A, Romics I, Fintha A, et al. Changes of protein expression in prostate cancer having lost its androgen sensitivity. Int Urol Nephrol. 2015;47:1149-54 pubmed publisher
  13. Bengtsson D, Schrøder H, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab. 2015;100:1689-98 pubmed publisher
  14. Chen T, Cho H, Wang W, Nguyen J, Jhaveri N, Rosenstein Sisson R, et al. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. Cancer Lett. 2015;358:144-51 pubmed publisher
  15. Fang Q, Inanç B, Schamus S, Wang X, Wei L, Brown A, et al. HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β. Nat Commun. 2014;5:5513 pubmed publisher
  16. Ramirez Y, Mladek A, Phillips R, Gynther M, Rautio J, Ross A, et al. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther. 2015;14:111-9 pubmed publisher
  17. Castro G, Cayado Gutiérrez N, Zoppino F, Fanelli M, Cuello Carrión F, Sottile M, et al. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress Chaperones. 2015;20:253-65 pubmed publisher
  18. Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, et al. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol. 2014;44:591-9 pubmed publisher
  19. Castro G, Cayado Gutiérrez N, Moncalero V, Lima P, De Angelis R, Chavez V, et al. Hsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. Cell Stress Chaperones. 2012;17:779-90 pubmed publisher
  20. Uno M, Oba Shinjo S, Camargo A, Moura R, Aguiar P, Cabrera H, et al. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo). 2011;66:1747-55 pubmed
  21. Caldera V, Mellai M, Annovazzi L, Piazzi A, Lanotte M, Cassoni P, et al. Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres. J Oncol. 2011;2011:314962 pubmed publisher
  22. Brell M, Ibanez J, Tortosa A. O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction. BMC Cancer. 2011;11:35 pubmed publisher
  23. Horbinski C, Hamilton R, Lovell C, Burnham J, Pollack I. Impact of morphology, MIB-1, p53 and MGMT on outcome in pilocytic astrocytomas. Brain Pathol. 2010;20:581-8 pubmed publisher
  24. Cooper W, Kohonen Corish M, Chan C, Kwun S, McCaughan B, Kennedy C, et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology. 2008;52:613-22 pubmed publisher